Immunome Inc. Common Stock (IMNM)
Stock · NASDAQ · Health Care
$16.47as of 10/16/2026
Price chart
Active signals
IMNM Signal Track Record
How signals performed across all stocks →What IMNM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +4.3% | 55% | September 15, 2026 |
| Bollinger Band Breakout | 26 | +2.9% | 54% | August 19, 2026 |
| Bollinger Band Breakdown | 19 | +10.4% | 79% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +4.3% | 70% | June 23, 2026 |
| Any 20-session window (baseline) | +2.1% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMNM
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan r…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 247
- Website
- immunome.com/
Fundamentals
- 1-day range
- $17.08$17.61
- Market cap
- $2.92B
- P/E (trailing)
- —
- P/E (forward)
- -7.17
- EPS (trailing)
- $-2.51
- Dividend yield
- —
- Beta
- 2.65
- Avg. volume
- 1.19M
How Immunome Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 3, 2026 · via SEC EDGAR / Finnhub
Forecasts
15 analyst ratings
Immunome Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IMNMImmunome Inc. Common Stock$16.47▼ 5.34%Market cap $2.92BP/E —$13.54$30.06
- IRONDisc Medicine Inc. Common Stock$56.84▲ 0.34%Market cap $2.97BP/E —$40$99.5
- SUPNSupernus Pharmaceuticals Inc. Common Stock$37.88▼ 4.27%Market cap $2.72BP/E —$39.36$59.68
- QUREuniQure N.V. Ordinary Shares$21.78▼ 3.29%Market cap $3.15BP/E —$8.73$71.5
- AMLXAmylyx Pharmaceuticals Inc. Common Stock$26.34▼ 4.74%Market cap $2.69BP/E —$10.83$41.14
- MBXMBX Biosciences Inc. Common Stock$49.61▼ 2.17%Market cap $3.19BP/E —$12.94$72.64
- TRVITrevi Therapeutics Inc. Common Stock$11.88▼ 1.90%Market cap $2.63BP/E —$9.28$20.22
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMNM Immunome Inc. Common Stock | $2.92B | — | $16.47 | ▼ 5.34% | $13.54$30.06 |
| IRON Disc Medicine Inc. Common Stock | $2.97B | — | $56.84 | ▲ 0.34% | $40$99.5 |
| SUPN Supernus Pharmaceuticals Inc. Common Stock | $2.72B | — | $37.88 | ▼ 4.27% | $39.36$59.68 |
| QURE uniQure N.V. Ordinary Shares | $3.15B | — | $21.78 | ▼ 3.29% | $8.73$71.5 |
| AMLX Amylyx Pharmaceuticals Inc. Common Stock | $2.69B | — | $26.34 | ▼ 4.74% | $10.83$41.14 |
| MBX MBX Biosciences Inc. Common Stock | $3.19B | — | $49.61 | ▼ 2.17% | $12.94$72.64 |
| TRVI Trevi Therapeutics Inc. Common Stock | $2.63B | — | $11.88 | ▼ 1.90% | $9.28$20.22 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- William Blair Initiates Coverage On Immunome with Outperform Ratingbenzinga · 10/16/2026
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/6/2026
- Benzinga's Volume MoversBenzinga · 10/5/2026
- Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed?Yahoo · 10/2/2026
- Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run ContinuesYahoo · 10/1/2026
- Stifel Initiates Coverage On Immunome with Hold Rating, Announces Price Target of $24Benzinga · 10/1/2026
- Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid TumorsYahoo · 9/30/2026
- Immunome Receives FDA Clearance For Its Investigational New Drug Application For IM-1340 To Treat Advanced Solid TumorsBenzinga · 9/30/2026
- Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32Benzinga · 9/21/2026
Insider Activity
Insider Actions →- Jack Higgins · September 11, 2026 · Option Exercise18.0K @ $1.35
- Jack Higgins · September 11, 2026 · Gift8.8K
- Jack Higgins · September 11, 2026 · Sale13.2K @ $25.32
- Isaac Barchas · August 12, 2026 · Sale11.0K @ $27.25
- Isaac Barchas · August 11, 2026 · Sale62.3K @ $26.23
- Isaac Barchas · August 10, 2026 · Sale10.1K @ $26.07
- Isaac Barchas · August 7, 2026 · Sale15.2K @ $26.06
- Isaac Barchas · August 6, 2026 · Sale20.8K @ $26.06
- Kinney Horn · August 4, 2026 · Option Exercise40.3K @ $10.6
- Kinney Horn · August 4, 2026 · Option Exercise50.4K @ $12.92
- Kinney Horn · August 4, 2026 · Sale90.6K @ $25.09
- Jack Higgins · July 23, 2026 · Grant76.5K
- Sandra G. Stoneman · July 23, 2026 · Grant76.5K
- Sandra G. Stoneman · July 23, 2026 · Grant38.3K
- Clay B. Siegall · July 23, 2026 · Grant360.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 113.55M
- Total value held
- $2.06B
- Institutional holders
- 193
- Unknown16.97M
- Unknown16.36M
- Unknown8.17M
- Unknown5.56M
- Unknown5.40M
- Unknown4.79M
- Unknown4.73M
- Unknown4.43M
- Unknown4.10M
- Unknown3.61M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Immunome files Nasdaq inducement grant report, sees higher volume
Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.
Immunome files Nasdaq inducement grant report, sees higher volume. Immunome disclosed inducement grants in a filing required by Nasdaq Listing Rule 5635(c)(4). The disclosure shows the company is meeting reporting obligations for equity compensation. At the same time, the stock appeared among Benzinga’s recent volume movers, indicating a noticeable increase in trading activity. These items together suggest regulatory compliance and heightened market attention.